Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing GLSI-100, an immunotherapy vaccine that combines a HER2-derived peptide with GM-CSF to prevent breast cancer recurrences in HER2-positive patients. The company is advancing the candidate through a global Phase III clinical trial and has received Fast Track designation from the U.S. FDA.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -3.8 | — |
| Q3 2025 | 0 | — | -4.2 | — |
| Q4 2025 | 0 | — | -7.9 | — |
| Q1 2026 | 0 | — | -5.7 | — |
| Q2 2026 | 0 | — | -4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Cartesian Therapeutics, Inc. (RNAC), Lyell Immunopharma, Inc. (LYEL), TON Strategy Co (TONX), Invivyd, Inc. (IVVD), Neostellar Capital Corp. (NSLR), TROOPS, Inc. (TROO)